SciCombinator

Discover the most talked about and latest scientific content & concepts.

M Takahashi, S Nishida, M Nakamura, M Kobayashi, K Matsui, E Ito, A Usui and Y Inoue
Abstract
To investigate the rate of and risk factors for restless legs syndrome (RLS) augmentation in Japanese patients receiving pramipexole (PPX) treatment. Records of 231 consecutive patients with idiopathic RLS who received PPX therapy for more than one month in a single sleep disorder center were analyzed retrospectively. Augmentation was diagnosed based on the Max Planck Institute criteria; associated factors were identified by logistic regression analysis. Mean age at PPX initiation was 60.6 ± 14.9 years and mean treatment duration was 48.5 ± 26.4 months. Augmentation was diagnosed in 21 patients (9.1%). Daily PPX dose and treatment duration were significantly associated with augmentation. By analyzing the receiver operating characteristic curve, a PPX dose of 0.375 mg/day was found to be the optimal cut-off value for predicting augmentation. After stratifying patients according to PPX treatment duration, at median treatment duration of 46 months, optimal cut-off values for daily doses were 0.375 and 0.500 mg/day for <46 months and ≥46 months of treatment, respectively. The RLS augmentation with PPX treatment in Japanese patients was occurred at rate of 9.1%, being quite compatible with previously reported rates in Caucasian patients. The symptom could appear within a relatively short period after starting the treatment in possibly vulnerable cases even with a smaller drug dose. Our results support the importance of keeping doses of PPX low throughout the RLS treatment course to prevent augmentation.
Tweets*
2
Facebook likes*
0
Reddit*
1
News coverage*
0
Blogs*
0
SC clicks
0
Concepts
Ropinirole, Pramipexole, Receiver operating characteristic, Logistic regression, Max Planck Society, Regression analysis, Restless legs syndrome
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com